CompletedNot Applicable

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Italy60 participantsStarted 2025-01-01

Plain-language summary

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosis of diabetic macular edema, diabetic retinopathy Exclusion Criteria: * previous ocular surgery, history of vitreoretinal and/or retinal vascular diseases, uveitis, myopia over 6 dioptres, significant corneal and/or lens opacity, glaucoma, ocular MNV related to other causes than nAMD, geographic atrophy, subretinal fibrosis, previous treatments for MNV

What they're measuring

Epivascular glia regression

Timeframe: From January 2025 to January 2026

Macular pigment changes

Timeframe: From January 2025 to January 2026

Trial details

NCT IDNCT07526857

SponsorFederico II University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-01

View on ClinicalTrials.gov More Diabetic Retinopathy, DR trials